Nyxoah (NYXH) Current Deferred Revenue (2024 - 2025)
Nyxoah's quarterly Current Deferred Revenue came in at $1.0 million in Q4 2025, up 732.35% year-on-year from $125025.7 in Q4 2024, and up 732.35% quarter-over-quarter from $125025.7 in Q4 2024.
Nyxoah has reported Current Deferred Revenue for 2 years, with the latest figure at $1.0 million in Q4 2025.
- For the quarter ending Q4 2025, Current Deferred Revenue rose 732.35% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (up 732.35% YoY), and the FY2025 full-year result was $1.0 million, up 732.35% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $1.0 million, up from $125025.7 in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.0 million in Q4 2025, with the low at $125025.7 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 156.17 Bn | 151.78 Bn | 1.83 Bn |
| 2 | Becton Dickinson | 41.51 Bn | 40.49 Bn | 2.15 Bn |
| 3 | Resmed | 30.43 Bn | 28.77 Bn | 890.98 Mn |
| 4 | West Pharmaceutical Services | 22.78 Bn | 22.26 Bn | 296.40 Mn |
| 5 | Solventum | 13.39 Bn | 13.39 Bn | 1.10 Bn |
| 6 | Cooper Companies | 12.33 Bn | 12.20 Bn | 695.20 Mn |
| 7 | Align Technology | 11.65 Bn | 10.59 Bn | 736.59 Mn |
| 8 | Baxter International | 9.81 Bn | 7.77 Bn | 891.00 Mn |
| 9 | Aptargroup | 7.39 Bn | 7.19 Bn | 351.91 Mn |
| 10 | Nyxoah | 1,248.49 | 1,248.49 | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 125,025.66 |